An Alzheimer’s Win: How Lilly Designed Donanemab Trial To Succeed

Phase II Results May Support Accelerated Approval

 
• By Mandy Jackson
Brainstorming creative idea
Lilly CEO David Ricks outlined the path to Phase II success for donanemab in Alzheimer's disease • Source: Shutterstock

More from Clinical Trials

More from R&D